Xalud Therapeutics develops therapies for the treatment of neuro-inflammatory diseases. It offers a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group.

Research Grants 8 show all


$299.3K
2011

$996.4K
2012

$1.6M
2013

$566.3K
2014

$2.8M
2018

Patents 29show all

    Clinical Trials 4show all

    3Phase 11Phase 2

    SEC Filings show all


    2
    D

    Contact Information

    30 Hill Street
    San Francisco, CA 94110
    United States

    Overview

    Total FundingEmployeesLast Funding DateStatus
    $12,300,0001-102020-03-06Operating

    Crunchbase Investment Rounds

    DateAmountRoundValuationLead InvestorOther Investors
    2020-03-06$5,000,000Series Unknown
    2015-07-16$7,300,000Series Unknown